⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348640 | 1.00 | — | — | |
| SCHEMBL1684074 | 1.00 | — | — | |
| Hydrogen Sulfide SCHEMBL5437546 | 0.97 | — | — | |
| SCHEMBL3340031 | 0.97 | — | — | |
| Bromide SCHEMBL1671440 | 0.97 | — | — | |
| SCHEMBL10784233 | 0.82 | ACE2 (0.50) | — | |
| SCHEMBL540008 | 0.78 | TRPA1 (0.37) | — | |
| SCHEMBL364329 | 0.77 | — | — | |
| SCHEMBL5139179 | 0.76 | GABRR1 (0.72) | — | |
| SCHEMBL341804 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4341246-A1 | A FACILE AND ODOR-FREE APPROACH TO CONVERT SULFONYL UREA DERIVATIVES TO CHALCOGENIDE SULFONYL UREA DERIVATIVES | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4341246-A1 | A FACILE AND ODOR-FREE APPROACH TO CONVERT SULFONYL UREA DERIVATIVES TO CHALCOGENIDE SULFONYL UREA DERIVATIVES | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3897833-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-11090283-B2 | Solid forms of selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210128513-A1 | NON-INVASIVE METHOD OF EVALUATING BREAST CANCERS FOR SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) THERAPY | UN IVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-05-06 | — | — | US | disclosed |
| US-10987334-B2 | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2011085385-A1 | METHODS OF TREATING MEIBOMIAN GLAND DYSFUNCTION | GTX, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1501804-B1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| WO-2007027582-A2 | TREATING RENAL DISEASE, BURNS, WOUNDS AND SPINAL CORD INJURY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1501804-A1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6818774-B2 | 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003091219-A1 | ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | disclosed |
| CN-87104582-A | The method of the heterogeneous ring compound of preparation acidylate | — | 1988-01-20 | — | — | CN | disclosed |